Prima BioMed Conference Call to Discuss First Half of Fiscal Year 2013 Results
(firmenpresse) - SYDNEY, AUSTRALIA -- (Marketwire) -- 03/04/13 -- Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima," "the Company") today announced it will hold a conference call to discuss its results for the first half of its fiscal year 2013, the period from July 1 through December 31, 2012. The half year report was previously released on the 28th of February 2013 and is available through the Investor Relations section of the Company's website at .
The call is scheduled for Thursday, the 7th of March 2013 at 9:00am (Sydney local time). Conference call dial-in numbers are as follows:
Australia Toll Free
1 800 131 617
Australia Alternate Toll Free
1 800 838 758
USA & Canada
1 855 237 2970
Germany
0800 189 9369
The call will also be audio webcast with additional supplemental slides available via . Before launching the webcast, it is recommended to click on the link and then on "test your systems configuration."
A replay of the teleconference and webcast will be available through Prima's website following the live event.
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its current technology and expertise to develop innovative treatment options for patients and maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell product currently in clinical trials for ovarian cancer patients who are in remission.
Ms. Jessica Brown
Prima BioMed Ltd.
+1 (919) 710-9061
Mr. James Moses
Mandate Corporate
+61 (0) 420 991 574
Mr. Axel Muhlhaus
edicto GmbH
+49 (0) 69 905505-52
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.03.2013 - 01:12 Uhr
Sprache: Deutsch
News-ID 235768
Anzahl Zeichen: 0
contact information:
Town:
SYDNEY, AUSTRALIA
Kategorie:
Drugs
Diese Pressemitteilung wurde bisher 404 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Prima BioMed Conference Call to Discuss First Half of Fiscal Year 2013 Results"
steht unter der journalistisch-redaktionellen Verantwortung von
Prima BioMed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
